Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ETUDE NEOMEL: TRAITEMENT NEOADJUVANT PAR IMMUNOTHERAPIE DU MELANOME METASTATIQUE OPERABLE EN VIE REELLE (GCC)

NCT06586593 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT06586593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06586593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ETUDE NEOMEL: TRAITEMENT NEOADJUVANT PAR IMMUNOTHERAPIE DU MELANOME METASTATIQUE OPERABLE EN VIE REELLE (GCC)
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Observational
Overall status
Recruiting
Start date
March 24, 2023
Completion date
January 31, 2025
Enrollment
77 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma metastatic